- Home
- EQIX vs BMY Comparison
EQIX vs BMY Comparison
Compare EQIX & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EQIX | BMY |
|---|---|---|
| Founded | 1998 | 1887 |
| Country | United States | United States |
| Employees | N/A | 32500 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.1B | 123.7B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | EQIX | BMY |
|---|---|---|
| Price | $971.28 | $58.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 21 | 15 |
| Target Price | ★ $984.75 | $61.93 |
| AVG Volume (30 Days) | 706.3K | ★ 9.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | 2.12% | ★ 4.20% |
| EPS Growth | ★ 61.88 | N/A |
| EPS | ★ 13.76 | N/A |
| Revenue | ★ $5,998,545,000.00 | N/A |
| Revenue This Year | $12.33 | N/A |
| Revenue Next Year | $8.88 | N/A |
| P/E Ratio | $70.68 | ★ $17.26 |
| Revenue Growth | ★ 7.85 | N/A |
| 52 Week Low | $701.41 | $42.52 |
| 52 Week High | $992.90 | $62.89 |
Technical Indicators
Market Signals| Indicator | EQIX | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 66.67 | 46.44 |
| Support Level | $759.85 | $46.16 |
| Resistance Level | $985.13 | $62.47 |
| Average True Range (ATR) | 21.55 | 1.13 |
| MACD | -3.81 | -0.46 |
| Stochastic Oscillator | 82.39 | 18.29 |
Price Performance
Historical ComparisonAbout EQIX Equinix Inc. REIT
Equinix is one of the leading providers of cloud- and carrier-neutral data centers, offering colocation and interconnection services to hyperscalers and businesses. Equinix operates 270 properties in 77 metropolitan areas across 36 countries, serving over 10,000 customers. About 70% of Equinix's revenue comes from renting physical space, which allows hyperscalers and other clients to store servers, data storage, and networking equipment. The other 30% of revenue is generated primarily through interconnection services (20%) and other managed services (10%).
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.